Agios Pharmaceuticals, Inc. (AGIO) Revenue by Segment & Business Profile
PYRUKYND (mitapivat) for hemolytic anemias in PK deficiency and sickle cell disease was 100.0% of Agios Pharmaceuticals, Inc.'s revenue, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AGIOAgios Pharmaceuticals, Inc.Follow AGIO — free
—
Price chart with a free account
- Market cap
- 2.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
What the company does
Agios Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector. Trailing twelve-month revenue: $98.3 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Commercial therapies
Revenue by geography
latest quarter · company segment note| Region | Revenue | Share | y/y |
|---|---|---|---|
| United States | 41M | 91.4% | +236.7% |
| Outside the US | 4M | 8.6% | +1159.2% |
Agios Pharmaceuticals, Inc. — questions
- What does Agios Pharmaceuticals, Inc. do?
- Agios Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector. Trailing twelve-month revenue: $98.3 million as of 2026-06-30.
- How does Agios Pharmaceuticals, Inc. make money?
- By the lines it reports in its SEC filings: PYRUKYND (mitapivat) for hemolytic anemias in PK deficiency and sickle cell disease 100.0% of revenue.
Every figure on this page comes from Agios Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.